Lv4
562 积分 2021-05-08 加入
Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease
1天前
已完结
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer
1天前
已完结
Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
1天前
已完结
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin–Unresponsive Non–Muscle Invasive Bladder Cancer
1天前
已完结
Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
1天前
已完结
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non–muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis
1天前
已完结
Lights and Shadows of Bacillus Calmette-Guérin (BCG)-exposed and BCG-unresponsive Definitions: A Practical Overview
1天前
已完结
Bacillus Calmette-Guérin–exposed Non–muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design
1天前
已完结
Cost‐effectiveness analysis of different treatment modalities in BCG‐unresponsive NMIBC
1天前
已完结
Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer?
1天前
求助中
皖公网安备34019202002308
